Firazyr self administration will be key to Shire growth as HAE competition heats up
This article was originally published in Scrip
Executive Summary
While Shire's FAST-3 Phase III trial in which its bradykin B2 receptor antagonist, Firazyr (icatibant) significantly outperformed placebo in the treatment of hereditary angioedema (HAE) should tick an outstanding box with the US FDA and open up the US market to the drug, the success of a separate European trial on the self-administration of Firazyr may prove to be a more significant development for the specialty biopharmaceutical company, and for the rest of the HAE market.